<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04000152</url>
  </required_header>
  <id_info>
    <org_study_id>IGX1-NIP-CS-18-05</org_study_id>
    <nct_id>NCT04000152</nct_id>
  </id_info>
  <brief_title>RCT Study to Validate niPGT-A Clinical Benefit.</brief_title>
  <acronym>niPGT-A_RCT</acronym>
  <official_title>Randomized Controlled Clinical Study to Assess the Benefit of Non-invasive PGT-A, by the Analysis of Spent Blastocyst Media, as a Tool for Embryo Prioritization in Infertile Patients Undergoing Assisted Reproduction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Igenomix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Igenomix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chromosomal aneuploidies are linked with spontaneous miscarriages and abnormal offspring in&#xD;
      human pregnancies. In addition, some types of aneuploidy are reported to prevent&#xD;
      implantation. Thus, there is a need to identify the embryos with highest implantation&#xD;
      potential on in vitro fertilization (IVF) programs.&#xD;
&#xD;
      Since embryo morphology and kinetics have a weak association with embryo ploidy,&#xD;
      trophectoderm biopsy plus Next-Generation Sequencing (NGS) is becoming a very popular&#xD;
      approach to determine the embryo chromosomal status. This technique is called Preimplantation&#xD;
      Genetic Testing for Aneuploidy (PGT-A). Although shown to be efficient, it is invasive for&#xD;
      the embryo, requires specific technical skills and it remains expensive. Therefore, the&#xD;
      development of a non-invasive, rapid and cheaper method for assessing embryo ploidy status&#xD;
      would represent a progress in the field of IVF.&#xD;
&#xD;
      The non-invasive approach has been explored by some groups that analyzed the Spent Blastocyst&#xD;
      Medium (SBM) where the embryo was incubated up to the time of transfer or freezing. In daily&#xD;
      routine, this media is discarded after finishing the culture of the embryo. Importantly,&#xD;
      though, this media reportedly contains traces of embryonic cell-free DNA (cfDNA) that can&#xD;
      represent the genetic load of the embryo.&#xD;
&#xD;
      On the basis of that, the hypothesis of this study is that embryo prioritization according to&#xD;
      the analysis of the embryonic cfDNA in the SBM could improve ongoing pregnancy rate in 10&#xD;
      percentual points compared to standard blastocyst transfer based on morphology.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current Preimplantation Genetic Testing for Aneuploidy (PGT-A) techniques analyze the full&#xD;
      chromosome content of a single or few cells with high sensitivity and specificity using&#xD;
      Next-Generation Sequencing (NGS). Although shown to be efficient, the technique suffers from&#xD;
      some limitations. It requires an embryo biopsy, specific technical skills and it still&#xD;
      remains expensive. Therefore, non-invasive techniques for assessing embryo ploidy status are&#xD;
      sought as an alternative. Such non-invasive approaches would have various advantages over&#xD;
      current strategies, including the elimination of a costly micromanipulation biopsy procedure&#xD;
      and the avoidance of risks associated with cell removal. Furthermore, it would be more&#xD;
      advantageous, especially for those patients who undergo in vitro fertilization (IVF)&#xD;
      treatment but do not have PGT-A indication or they are not willing to have their embryos&#xD;
      tested with invasive techniques.&#xD;
&#xD;
      One of the recent advances in the field is the identification of embryonic cell-free DNA&#xD;
      (cfDNA) during embryo culture in the lab. It is released to the culture drop (SBM) and&#xD;
      represents the chromosome content of the embryo. In a recent pilot study, we analyzed the&#xD;
      concordance rates between trophectoderm (TE) biopsy and SBM. In SBM collected on day 6/7 of&#xD;
      development, the results were concordant with TE biopsies in 84% of samples, with a&#xD;
      false-positive rate of 8.6% and a false-negative rate of 2.5%. These findings are encouraging&#xD;
      and were the base for the design of the current RCT study.&#xD;
&#xD;
      The main objective of this study is to evaluate the potential clinical benefits of a new&#xD;
      non-invasive method for PGT-A, based on the analysis of the embryonic cfDNA released into&#xD;
      SBM.&#xD;
&#xD;
      Considering a dropout rate of around 30% (treatment or monitoring failures and no day 6/7&#xD;
      blastocysts to transfer), a total of 872 participants will be randomized before the ovum&#xD;
      pick-up. They will be allocated on a balanced way (1:1 ratio) in one of the two arms: 1)&#xD;
      Single Embryo Transfer (SET) on day 6/7 with deferred blastocyst transfer based on the&#xD;
      chromosomal status according to the analysis of the SBM; 2) SET on day 6/7 with deferred&#xD;
      blastocyst transfer based on embryo morphology. Reproductive outcomes (defined following The&#xD;
      International Glossary on Infertility and Fertility Care, 2017) will be compared between the&#xD;
      two groups.&#xD;
&#xD;
      Data exported from the clinical histories and source documents will be duly codified to&#xD;
      protect the clinical and personal information of patients in accordance with the current&#xD;
      legislation. This information will be exported to an electronic Case Report Form (eCRF). An&#xD;
      interim analysis of this data is planned once 30% of the recruitment has been reached.&#xD;
      Besides, the study will be overseen by an independent Data Monitoring Committee after 30% of&#xD;
      patientsÂ´ recruitment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2019</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-invasive analysis of the chromosomal status of the embryo</measure>
    <time_frame>7 days</time_frame>
    <description>Number and structure of the embryo chromosomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>Over 12 weeks</time_frame>
    <description>Number of ongoing pregnancies per single embryo transfer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NGS results of the SBM</measure>
    <time_frame>7 days at least</time_frame>
    <description>Informativity rates and prioritization category of the SBM analysis results with embryo development, culture conditions and collection time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-Invasive Prenatal Testing (NIPT)</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Incidence of chromosomal abnormalities in NIPT within ongoing pregnancy cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical miscarriage rate</measure>
    <time_frame>Up to 6 months after the ovum pick-up</time_frame>
    <description>Number of clinical miscarriages per total number of ongoing pregnancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the Products of Conception (POC)</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <description>Incidence of chromosomal abnormalities in POC within miscarriage cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative ongoing pregnancy rate</measure>
    <time_frame>Over 6 months after the ovum pick-up</time_frame>
    <description>Cumulative ongoing pregnancy rate per patient in the 6 months after the pick-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to get an ongoing pregnancy</measure>
    <time_frame>Up to 6 months after the ovum pick-up</time_frame>
    <description>Time to get an ongoing pregnancy within the 6 months after the pick-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>Over 40 weeks</time_frame>
    <description>Number of babies born per embryo transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative live birth rate</measure>
    <time_frame>Over 6 months after the ovum pick-up</time_frame>
    <description>Cumulative live birth rate per patient in the 6 months after the pick-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obstetrical outcomes comparison</measure>
    <time_frame>Over 40 weeks</time_frame>
    <description>To compare birth weight, gestational age, APGAR, type of delivery, pregnancy complications, etc.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1108</enrollment>
  <condition>Aneuploidy</condition>
  <condition>Chromosome Abnormality</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Control group (group 1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Deferred single blastocyst transfer with blastocyst selection according to morphology.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group (group 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deferred single blastocyst transfer with blastocyst selection according to the analysis of the spent culture media (niPGT-A).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>niPGT-A</intervention_name>
    <description>Two scenarios should be considered according to the results in the SBM analysis:&#xD;
The couple decides to transfer the blastocyst selected according to the SBM result (blastocyst prioritization system).&#xD;
The couple decides to biopsy the blastocysts (if SBM results show low euploidy score). This PGT-A analysis will be offered for free but the outcome of these transfers will be excluded for the analysis per completed protocol. However, all transfers will be included in the intention-to-treat analysis.</description>
    <arm_group_label>Intervention group (group 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Morphology criteria</intervention_name>
    <description>Embryos for transfer will be selected by the only applicable technique, the assessment of morphology according to GardnerÂ´s criteria, which is the most standardized method.</description>
    <arm_group_label>Control group (group 1)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients whose written informed consent approved by the Ethics Committee (EC) has been&#xD;
             obtained, after having been duly informed of the nature of the study and voluntarily&#xD;
             accepted to participate after being fully aware of the potential risks, benefits and&#xD;
             any discomfort involved.&#xD;
&#xD;
          -  IVF patients intending to undergo deferred day 6/7 blastocyst SET for any medical&#xD;
             indication.&#xD;
&#xD;
          -  All the oocytes/embryos from the cycle should follow the laboratory protocol described&#xD;
             in the study (embryo culture and vitrification on day 6/7).&#xD;
&#xD;
          -  ICSI, IVF or ICSI/IVF performed in fresh own oocytes from couples not undergoing&#xD;
             PGT-A. Note: Donor sperm is allowed.&#xD;
&#xD;
          -  Female age: 20-40 years, both included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A known abnormal karyotype if the couple provides it at consultation. If not,&#xD;
             karyotype is not compulsory.&#xD;
&#xD;
          -  Couples planning to undergo PGT-M or PGT-SR cases will be excluded.&#xD;
&#xD;
          -  Surrogate pregnancy (in those countries where it is allowed).&#xD;
&#xD;
          -  ERA test and embryo transfer according to ERA result.&#xD;
&#xD;
          -  Time-lapse culture systems are not allowed after day 4 of culture.&#xD;
&#xD;
          -  Presence of pathologies or malformations that affect the uterine cavity such as&#xD;
             polyps, intramural myomas â¥ 4cm or submucosal, septum or hydrosalpinx during the&#xD;
             patient's participation in the study. Patients suffering these pathologies before or&#xD;
             after their inclusion in the study can participate if the pathology is corrected&#xD;
             before performing any study procedure.&#xD;
&#xD;
          -  Any illness or medical condition that is unstable or which, according to medical&#xD;
             criteria, may put at risk the patient's safety and her compliance in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>IVF patients between 20 and 40 years of age undergoing fertility treatment with their own oocytes, with no intention or medical indication for PGT-A.</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Rubio, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Igenomix S.L.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos SimÃ³n, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Igenomix S.L.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlos GÃ³mez, BSc MSc</last_name>
    <phone>+34 963905310</phone>
    <email>carlos.gomez@igenomix.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carmen Rubio, PhD</last_name>
    <phone>+34 963905310</phone>
    <email>carmen.rubio@igenomix.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fertility Associates of California (FSAC)</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91361</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mousa Shamonki, MD</last_name>
      <phone>805-719-7531</phone>
      <email>mshamonki@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mousa Shamonki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Florida Institute for Reproductive Medicine (IVFMD)</name>
      <address>
        <city>Florida City</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston IVF Fertility Clinic</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Crecer: Centro de ReproducciÃ³n y GenÃ©tica Humana</name>
      <address>
        <city>Mar Del Plata</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia PenÃ©, BSc</last_name>
      <email>aliciapene@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>DÃ©bora Petrona, MD</last_name>
      <email>debopet@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alicia PenÃ©, BSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saresa - ReproducciÃ³n Humana Asistida</name>
      <address>
        <city>Salta</city>
        <zip>4400</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MarÃ­a Florencia GimÃ©nez Marcuzzi, BSc</last_name>
      <phone>+54 387-422-2272</phone>
      <email>f.gimenez@saresa.com.ar</email>
    </contact>
    <contact_backup>
      <last_name>Juan JosÃ© Aguilera, MD</last_name>
      <phone>+54 387-422-2272</phone>
      <email>jaguilera@saresa.com.ar</email>
    </contact_backup>
    <investigator>
      <last_name>MarÃ­a Florencia GimÃ©nez Marcuzzi, BSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nilo Frantz - Centro de ReproduÃ§Ã£o Humana</name>
      <address>
        <city>Boa Vista</city>
        <state>Porto Alegre</state>
        <zip>91330-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adriana Bos-Mikich, MD</last_name>
      <phone>+ 55 51 3328 4680</phone>
      <email>adriana.bosmikich@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nilo Frantz, MD</last_name>
      <phone>+55 51 3328 4680</phone>
      <email>nilo@nilofrantz.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Nilo Frantz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vida - Centro de Fertilidade</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>22793-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MarÃ­a Cecilia de Almeida Cardoso, MD</last_name>
      <phone>+55 21 2493 0758</phone>
      <email>mceciliacardoso@vidafertil.com.br</email>
    </contact>
    <investigator>
      <last_name>MarÃ­a Cecilia de Almeida Cardoso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marine Poulain, PhD</last_name>
      <phone>+33 (0)1.46.25.35.21</phone>
      <email>marine.poulain@hopital-foch.com</email>
    </contact>
    <investigator>
      <last_name>Marine Poulain, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marc Ayoubi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SocietÃ  Italiana Studi di Medicina della Riproduzione (S.I.S.M.e.R.)</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Gianaroli, MD</last_name>
      <phone>051 307307</phone>
      <email>pazienti@sismer.it</email>
    </contact>
    <investigator>
      <last_name>Luca Gianaroli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Procreazione Assistita DEMETRA</name>
      <address>
        <city>Firenze</city>
        <zip>50141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesca Benini, MSc PhD</last_name>
      <phone>(+39) 055 488709</phone>
      <email>benini@centrodemetra.com</email>
    </contact>
    <contact_backup>
      <last_name>Claudia Livi, MD</last_name>
      <phone>(+39) 055 488709</phone>
      <email>livi@centrodemetra.com</email>
    </contact_backup>
    <investigator>
      <last_name>Francesca Benini, MSc PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Promea S.p.A</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Monaco, MD</last_name>
      <phone>+39 011-664-0800</phone>
      <email>amonaco@promea.net</email>
    </contact>
    <investigator>
      <last_name>Antonio Monaco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ruber Internacional</name>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josu Franco Iriarte, PhD</last_name>
      <phone>(+34) 913875017</phone>
      <email>josufranco@hotmail.es</email>
    </contact>
    <contact_backup>
      <last_name>Amelia Villa, MD</last_name>
      <phone>(+34) 91387504</phone>
      <email>amelia.villa@ruberinternacional.es</email>
    </contact_backup>
    <investigator>
      <last_name>Elena Carrillo de Albornoz Riaza, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BahÃ§eci Health Group</name>
      <address>
        <city>Istanbul</city>
        <zip>34394</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meral Gultomruk, BSc</last_name>
      <phone>(+90) 2123103100</phone>
      <email>mgultomruk@bahceci.com</email>
    </contact>
    <contact_backup>
      <last_name>Mustafa BahÃ§eci, MD PhD</last_name>
      <phone>(+90) 2123103166</phone>
      <email>mbahceci@bahceci.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mustafa BahÃ§eci, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Japan</country>
    <country>Mexico</country>
  </removed_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>June 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2019</study_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blastocyst</keyword>
  <keyword>Non-invasive</keyword>
  <keyword>PGT-A</keyword>
  <keyword>Aneuploidy</keyword>
  <keyword>Spent culture medium</keyword>
  <keyword>Trophectoderm biopsy</keyword>
  <keyword>Sustained implantation</keyword>
  <keyword>Miscarriage</keyword>
  <keyword>Livebirth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Chromosome Disorders</mesh_term>
    <mesh_term>Aneuploidy</mesh_term>
    <mesh_term>Chromosome Aberrations</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

